Actively Recruiting
Phase 2 Study of Enfortumab Vedotin and Pembrolizumab with Selective Bladder Preservation for Treating Muscle-Invasive Bladder Cancer
Led by Matthew Galsky · Updated on 2026-08-05
75
Participants Needed
5
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on patients with muscle-invasive bladder urothelial carcinoma MIBC. It investigates the combined use of enfortumab vedotin and pembrolizumab to evaluate their effect on clinical complete response rates and bladder-intact event-free survival. The study is a phase 2 trial aiming to explore selective bladder sparing as an alternative to cystectomy for patients with localized MIBC. Participants first receive three cycles of induction treatment with enfortumab vedotin dosed at 1.25 mgkg up to 125 mg plus pembrolizumab at 200 mg. After these cycles, patients undergo restaging involving MRI of the bladder, urine cytology, cystoscopy with transurethral resection of bladder tumor TURBT of visible tumors or resection sites, and random biopsies. Those who achieve a strict clinical complete response then receive maintenance treatment consisting of 14 cycles of pembrolizumab and enfortumab vedotin during the first six of these maintenance cycles. Patients with residual disease after restaging undergo cystectomy. During the study, participants will be monitored with imaging and laboratory tests to assess response and safety over time. The primary outcomes include the complete response rate at 9 weeks and bladder-intact event-free survival over 2 years. Secondary outcomes include safety evaluations and various survival measures up to 4 years. The study involves regular clinical visits for treatment administration and restaging procedures, with the total duration of participation spanning multiple years depending on response and maintenance treatment.
CONDITIONS
Brief Title
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Research Team
M
Matthew Galsky, MD
A
Ahran Lee
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here